<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01561079</url>
  </required_header>
  <id_info>
    <org_study_id>00051600</org_study_id>
    <nct_id>NCT01561079</nct_id>
  </id_info>
  <brief_title>Fetal and Infant Effects of Maternal Buprenorphine Treatment</brief_title>
  <official_title>Fetal and Infant Effects of Maternal Buprenorphine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research will track the longitudinal neurobehavioral development of the
      buprenorphine-exposed fetus across gestation through 1 month of age in an effort to determine
      the safety of this medication for use during gestation, the relationship between maternal
      physiologic changes due to buprenorphine administration and newborn functioning, and to
      determine potential fetal neurobehavioral markers that may predict Neonatal Abstinence
      Syndrome expression and infant neurobehavioral outcome. Comparisons to results from a similar
      project in methadone-exposed pregnancies will be made. This proposal seeks to advance the way
      the investigators inform the treatment of the opioid dependent woman during pregnancy and her
      infant after birth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an increase in the prevalence of illicit opiate use among women of childbearing age
      in many countries today. Methadone is the treatment of choice for opioid dependency during
      pregnancy in the US because it markedly diminishes withdrawal symptoms and craving and blocks
      opioid effects, however, in utero exposure results in significant depression of fetal
      neurobehaviors such as fetal heart rate and heart rate variability and fetal motor activity,
      and significant neonatal abstinence syndrome (NAS) in the majority of exposed infants. Since
      its approval in 2002, the prescription of buprenorphine for opioid dependence has increased
      dramatically but, as with methadone, this mediation is not approved for use during pregnancy.
      Currently, women treated with buprenorphine prior to pregnancy are transitioned to methadone
      treatment due to a lack of information regarding the effects of buprenorphine on the
      developing fetus and infant. Pilot work by this research team suggests that buprenorphine- as
      compared to methadone-exposed fetuses display more optimal neurobehavioral functioning in the
      second and third trimesters of pregnancy. Although these results are encouraging, there is a
      critical need to explore fully the effects of this medication on the fetus and infant to
      adequately advise care providers and patients regarding its use. This is particularly true
      given the imminent publication of a pivotal study comparing buprenorphine to methadone
      treatment during pregnancy which has suggested the optimality of buprenorphine for the
      treatment of opioid dependence during pregnancy, and is likely to result in increasing
      numbers of women being treated with off-label buprenorphine during pregnancy. This proposal
      seeks to explore the effect of buprenorphine on maternal physiology and fetal neurobehavioral
      functioning longitudinally as a measure of the development of the fetal nervous system.
      Additionally, the neurobehavioral profile and NAS of the buprenorphine-exposed infant up to
      one month will be delineated in an effort to provide information necessary to provide optimal
      pharmacologic and non-pharmacologic treatment of NAS. Furthermore, this group has previously
      explored similar parameters in methadone-exposed fetuses and infants, and results of this
      study can be compared to those historical data. These parameters will advance our
      understanding of the way the investigators view and implement the future pharmacologic
      treatment of the opiate dependent woman during pregnancy and her infant after birth, and
      inform clinicians, health insurance companies and regulatory agencies in the provision of
      optimal care to the opioid dependent pregnant woman and her offspring before and after birth.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fetal Heart Rate</measure>
    <time_frame>24, 28, 32 and 36 weeks of gestation</time_frame>
    <description>Fetal heart rate in beats per minute at time of trough and peak maternal buprenorphine levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal Heart Rate Variability</measure>
    <time_frame>24, 28, 32 and 36 weeks of gestation</time_frame>
    <description>Fetal heart rate variability at 24, 28, 32 and 36 weeks of gestation at times of trough and peak maternal buprenorphine levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Accelerations of Fetal Heart Rate</measure>
    <time_frame>24, 28, 32 36 weeks of gestation</time_frame>
    <description>Number of accelerations of fetal heart rate exhibited during the 60 minute recordings</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal Movement</measure>
    <time_frame>24, 28, 32, 36 weeks of gestation</time_frame>
    <description>Fetal movement (number x duration of fetal movements) during the 60 minute recordings at times of trough and peak maternal buprenorphine levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fetal Movement - Fetal Heart Rate Coupling</measure>
    <time_frame>24, 28, 32, 36 weeks of gestation</time_frame>
    <description>The integration between fetal movements and heart rate (FM-FHR coupling) was quantified as the proportion of time individual movements were associated with a change in FHR, using previously developed criteria. FM-FHR coupling reflects coactivation of the sympathetic and parasympathetic components of the autonomic nervous system.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Neonatal Abstinence Syndrome</condition>
  <arm_group>
    <arm_group_label>Maternal buprenorphine treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buprenorphine maintenance during pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.</description>
    <arm_group_label>Maternal buprenorphine treatment</arm_group_label>
    <other_name>Subutex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current opioid dependence as defined by Diagnostic and Statistical Manual of Mental
             Disorders (DSM) IV-R criteria

          -  18-40 years of age with uncomplicated singleton pregnancies

          -  Accurate gestational age dating verified by ultrasound

          -  Gestation of less than 34 weeks

          -  Stabilization on buprenorphine for one week prior to study procedures

        Exclusion Criteria:

          -  Complications of pregnancy, including gestational diabetes, polyhydramnios,
             hypertension, placenta previa or significant risk of preterm delivery (i.e.
             incompetent cervix)

          -  Evidence of fetal malformation detected by prenatal ultrasound

          -  Significant general maternal health problems that can affect fetal functioning,
             including Type I or gestational diabetes, alterations in thyroid functioning, HIV
             infection or hypertension.

          -  Significant maternal psychopathology that would preclude informed consent (i.e.
             schizophrenia)

          -  Alcohol dependency per DSM IV R criteria (see ascertainment methods below)

          -  Women stable on methadone maintenance (defined as more than 3 days of methadone
             dosing)

          -  Women entering drug treatment reporting using &quot;street&quot; methadone (for more than 3
             days)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauren M Jansson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Addiction and Pregnancy</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jansson LM, Dipietro JA, Velez M, Elko A, Williams E, Milio L, O'Grady K, Jones HE. Fetal neurobehavioral effects of exposure to methadone or buprenorphine. Neurotoxicol Teratol. 2011 Mar-Apr;33(2):240-3. doi: 10.1016/j.ntt.2010.09.003. Epub 2010 Sep 22.</citation>
    <PMID>20868741</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 22, 2012</study_first_posted>
  <results_first_submitted>March 8, 2017</results_first_submitted>
  <results_first_submitted_qc>August 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 28, 2017</results_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Buprenorphine</keyword>
  <keyword>Methadone</keyword>
  <keyword>Fetal neurobehavior</keyword>
  <keyword>Infant neurobehavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neonatal Abstinence Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from a comprehensive care treatment facility for pregnant and postpartum women with substance use disorders between Feb 2012 and March 2016</recruitment_details>
      <pre_assignment_details>Participants must have an opioid use disorder, a singleton, generally uncomplicated pregnancy, be between 18 and 40 years of age, have accurate gestational age dating of less than 34 weeks, willing to receive obstetric care at the center and deliver their infant at the hospital affiliated with the treatment facility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Maternal Buprenorphine Treatment</title>
          <description>Daily sublingual buprenorphine treatment of pregnant, opioid dependent women Subjects undergo maternal-fetal monitoring at any combination of the following gestational time periods: 24, 28,32, 36 weeks of gestation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="78"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fetal</title>
          <description>Daily sublingual buprenorphine treatment of pregnant, opioid dependent women Subjects completing any maternal-fetal monitoring at any combination of the following gestational ages: 24, 28, 32 36 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first substance use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at regular substance use</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.0" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of regular substance use upon treatment entry</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.5" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestational age upon treatment entry</title>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of time in treatment prior to delivery</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.1" spread="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Buprenorphine dose at 24 weeks if gestation</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.0" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Buprenorphine dose at 28 weeks if gestation</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Buprenorphine dose at 32 weeks if gestation</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Buprenorphine dose at 36 weeks if gestation</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.8" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Urine toxicology screenings during treatment</title>
          <units>number of screenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16.4" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Positive research urine toxicology screening at delivery</title>
          <units>percent positive urine tox. screenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.7" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fetal Heart Rate</title>
        <description>Fetal heart rate in beats per minute at time of trough and peak maternal buprenorphine levels</description>
        <time_frame>24, 28, 32 and 36 weeks of gestation</time_frame>
        <population>Participants active in the protocol at 24, 28, 32 and 36 weeks, respectively</population>
        <group_list>
          <group group_id="O1">
            <title>FHR 24 Weeks Trough</title>
            <description>Fetal heart rate in beats per minute at 24 weeks of gestation at trough</description>
          </group>
          <group group_id="O2">
            <title>FHR 28 Weeks Trough</title>
            <description>Fetal heart rate in beats per minute at 28 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O3">
            <title>FHR 32 Weeks Trough</title>
            <description>Fetal heart rate in beats per minute at 32 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O4">
            <title>FHR 36 Weeks Trough</title>
            <description>Fetal heart rate in beats per minute at 36 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O5">
            <title>FHR 24 Weeks Peak</title>
            <description>Fetal heart rate in beats per minute at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O6">
            <title>FHR 28 Weeks Peak</title>
            <description>Fetal heart rate in beats per minute at 28 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O7">
            <title>FHR 32 Peak</title>
            <description>Fetal heart rate in beats per minute at 32 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O8">
            <title>FHR 36 Peak</title>
            <description>Fetal heart rate in beats per minute at 36 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Heart Rate</title>
          <description>Fetal heart rate in beats per minute at time of trough and peak maternal buprenorphine levels</description>
          <population>Participants active in the protocol at 24, 28, 32 and 36 weeks, respectively</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.7" spread="5.8"/>
                    <measurement group_id="O2" value="143.3" spread="5.4"/>
                    <measurement group_id="O3" value="138.6" spread="6.0"/>
                    <measurement group_id="O4" value="136.3" spread="7.1"/>
                    <measurement group_id="O5" value="143.9" spread="6.4"/>
                    <measurement group_id="O6" value="141.0" spread="4.8"/>
                    <measurement group_id="O7" value="135.4" spread="6.3"/>
                    <measurement group_id="O8" value="131.3" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <p_value_desc>The p values were not adjusted for multiplicity The a priori threshold = .05</p_value_desc>
            <method>Hierarchical Linear Modeling</method>
            <method_desc>The p-value was calculated</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fetal Heart Rate Variability</title>
        <description>Fetal heart rate variability at 24, 28, 32 and 36 weeks of gestation at times of trough and peak maternal buprenorphine levels</description>
        <time_frame>24, 28, 32 and 36 weeks of gestation</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>FHRV 24 Trough</title>
            <description>Fetal heart rate variability at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O2">
            <title>FHRV 28 Trough</title>
            <description>Fetal heart rate variability at 28 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O3">
            <title>FHRV 32 Trough</title>
            <description>Fetal heart rate variability at 32 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O4">
            <title>FHRV 36 Trough</title>
            <description>Fetal heart rate variability at 36 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O5">
            <title>FHRV 24 Peak</title>
            <description>Fetal heart rate variability at 24 weeks gestation at the time of peak maternal buprenorphine levels</description>
          </group>
          <group group_id="O6">
            <title>FHRV 28 Peak</title>
            <description>Fetal heart rate variability at 28 weeks gestation at the time of peak maternal buprenorphine levels</description>
          </group>
          <group group_id="O7">
            <title>FHRV 32 Peak</title>
            <description>Fetal heart rate variability at 32 weeks gestation at the time of peak maternal buprenorphine levels</description>
          </group>
          <group group_id="O8">
            <title>FHRV 36 Peak</title>
            <description>Fetal heart rate variability at 36 weeks gestation at the time of peak maternal buprenorphine levels</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Heart Rate Variability</title>
          <description>Fetal heart rate variability at 24, 28, 32 and 36 weeks of gestation at times of trough and peak maternal buprenorphine levels</description>
          <population>Per protocol</population>
          <units>msec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="1.3"/>
                    <measurement group_id="O2" value="6.7" spread="1.9"/>
                    <measurement group_id="O3" value="7.5" spread="3.0"/>
                    <measurement group_id="O4" value="7.9" spread="2.1"/>
                    <measurement group_id="O5" value="4.9" spread="1.5"/>
                    <measurement group_id="O6" value="7.3" spread="1.8"/>
                    <measurement group_id="O7" value="7.0" spread="2.7"/>
                    <measurement group_id="O8" value="6.3" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.002</p_value>
            <method>Hierarchical Linear Modeling</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Accelerations of Fetal Heart Rate</title>
        <description>Number of accelerations of fetal heart rate exhibited during the 60 minute recordings</description>
        <time_frame>24, 28, 32 36 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Accelerations 24 Trough</title>
            <description>Accelerations in fetal heart rate at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O2">
            <title>Accelerations 28 Trough</title>
            <description>Accelerations in fetal heart rate at 28 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O3">
            <title>Accelerations 32 Trough</title>
            <description>Accelerations in fetal heart rate at 32 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O4">
            <title>Accelerations 36 Trough</title>
            <description>Accelerations in fetal heart rate at 36 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O5">
            <title>Accelerations 24 Peak</title>
            <description>Accelerations in fetal heart rate at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O6">
            <title>Accelerations 28 Peak</title>
            <description>Accelerations in fetal heart rate at 28 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O7">
            <title>Accelerations 32 Peak</title>
            <description>Accelerations in fetal heart rate at 32 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O8">
            <title>Accelerations36 Peak</title>
            <description>Accelerations in fetal heart rate at 36 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
        </group_list>
        <measure>
          <title>Accelerations of Fetal Heart Rate</title>
          <description>Number of accelerations of fetal heart rate exhibited during the 60 minute recordings</description>
          <units>accelerations</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="1.59" lower_limit="0" upper_limit="8"/>
                    <measurement group_id="O3" value="3.57" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O4" value="5.28" lower_limit="0" upper_limit="17"/>
                    <measurement group_id="O5" value="0.43" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O6" value="2.12" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O7" value="2.29" lower_limit="0" upper_limit="9"/>
                    <measurement group_id="O8" value="2.25" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>Hierarchical Linear Modeling</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fetal Movement</title>
        <description>Fetal movement (number x duration of fetal movements) during the 60 minute recordings at times of trough and peak maternal buprenorphine levels</description>
        <time_frame>24, 28, 32, 36 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fetal Movement 24 Trough</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O2">
            <title>Fetal Movement 28 Trough</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O3">
            <title>Fetal Movement 32 Trough</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O4">
            <title>Fetal Movement 36 Trough</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O5">
            <title>Fetal Movement 24 Peak</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O6">
            <title>Fetal Movement 28 Peak</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O7">
            <title>Fetal Movement 32 Peak</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O8">
            <title>Fetal Movement 36 Peak</title>
            <description>Fetal movement during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Movement</title>
          <description>Fetal movement (number x duration of fetal movements) during the 60 minute recordings at times of trough and peak maternal buprenorphine levels</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496.2" spread="752.0"/>
                    <measurement group_id="O2" value="1390.0" spread="795.4"/>
                    <measurement group_id="O3" value="1458.7" spread="674.6"/>
                    <measurement group_id="O4" value="1446.7" spread="979.5"/>
                    <measurement group_id="O5" value="1613.0" spread="575.6"/>
                    <measurement group_id="O6" value="1385.7" spread="674.5"/>
                    <measurement group_id="O7" value="1381.2" spread="830.7"/>
                    <measurement group_id="O8" value="1038.2" spread="756.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Hierarchical Linear Modeling</method>
            <method_desc>The reported p-value was calculated</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fetal Movement - Fetal Heart Rate Coupling</title>
        <description>The integration between fetal movements and heart rate (FM-FHR coupling) was quantified as the proportion of time individual movements were associated with a change in FHR, using previously developed criteria. FM-FHR coupling reflects coactivation of the sympathetic and parasympathetic components of the autonomic nervous system.</description>
        <time_frame>24, 28, 32, 36 weeks of gestation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FM-FHR 24 Trough</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O2">
            <title>FM-FHR 28 Trough</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O3">
            <title>FM-FHR 32 Trough</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O4">
            <title>FM-FHR 36 Trough</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of trough maternal buprenorphine level</description>
          </group>
          <group group_id="O5">
            <title>FM-FHR 24 Peak</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O6">
            <title>FM-FHR 28 Peak</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O7">
            <title>FM-FHR 32 Peak</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
          <group group_id="O8">
            <title>FM-FHR 36 Peak</title>
            <description>Fetal movement-fetal heart rate coupling during the 60 minute recordings at 24 weeks of gestation at time of peak maternal buprenorphine level</description>
          </group>
        </group_list>
        <measure>
          <title>Fetal Movement - Fetal Heart Rate Coupling</title>
          <description>The integration between fetal movements and heart rate (FM-FHR coupling) was quantified as the proportion of time individual movements were associated with a change in FHR, using previously developed criteria. FM-FHR coupling reflects coactivation of the sympathetic and parasympathetic components of the autonomic nervous system.</description>
          <units>percentage of time FM assoc w FHR change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="42"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="30"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.06"/>
                    <measurement group_id="O2" value="0.21" spread=".07"/>
                    <measurement group_id="O3" value="0.23" spread="0.10"/>
                    <measurement group_id="O4" value="0.25" spread="0.11"/>
                    <measurement group_id="O5" value="0.09" spread="0.06"/>
                    <measurement group_id="O6" value="0.20" spread="0.09"/>
                    <measurement group_id="O7" value="0.21" spread="0.10"/>
                    <measurement group_id="O8" value="0.20" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.002</p_value>
            <method>Hierarchical Linear Modeling</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Maternal Buprenorphine Treatment</title>
          <description>Buprenorphine maintenance during pregnancy
Buprenorphine: Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
Two severe adverse events were reported in the same infant patient. One infant had congenital heart disease and polydactyly</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>congenital heart disease</sub_title>
                <description>One infant born to a buprenorphine maintained mother was born with a congenital heart disease. The infant had a family history of congenital heart disease.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Severe adverse event</sub_title>
                <description>One infant born to a buprenorphine maintained mother in the protocol had polydactyly The infant had a family history of polydactyly</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiomegaly</sub_title>
                <description>2 fetal subjects had mild cardiomegaly on fetal sonogram</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>fetal arrythmia</sub_title>
                <description>One fetus had a cardiac arrhythmia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fetal growth restriction</sub_title>
                <description>One fetus was diagnosed with fetal growth restriction (but was average for gestational age at delivery)</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>psychiatric concern</sub_title>
                <description>One maternal subject developed a psychiatric concern warranting hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>maternal dehydration</sub_title>
                <description>One maternal subject developed decreased fetal HRV and fetal tachycardia, was dx with dehydration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis of pregnancy</sub_title>
                <description>Three participants developed cholestasis of pregnancy. All three had concurrent Hepatitis C infection and were therefore at increased risk for this condition.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <description>One subject developed bacterial vaginosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <description>One infant was born with congenital pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>choroid plexus cysts</sub_title>
                <description>One fetal subject had choroid plexus cysts on fetal sonogram</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>chorioamnionitis</sub_title>
                <description>Two maternal subjects had chorioamnionitis at delivery</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fetal stress at delivery</sub_title>
                <description>Two fetuses exhibited fetal stress at the time of delivery</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>nonreactive fetal tracing, fetal hear rate deceleration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Lauren M Jansson</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-550-5438</phone>
      <email>ljansson@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

